The pros at ProPharma Partners offer advice to biotechnology and pharmaceutical companies on everything from corporate strategy to clinical trials. The consulting firm, which is the European arm of US-based ProPharma Partners Group, assists companies with negotiating licensing deals, corporate partnerships, and mergers and acquisitions. ProPharma also helps its clients complete FDA regulatory applications in order to register and market newly-developed drug products. The group has offices in North America, Europe, and Japan, from which it serves such clients as Cambridge Laboratories, King Pharmaceuticals, Metabolex, ReGen Therapeutics Plc, and Replidyne.

Owners (and spouses) Tei Fu Chen and Oi-Lin Chen started Sunrider International in 1982. Sunrider Corporation has blended bits of traditional Chinese herbal medicine with modern multilevel marketing. The company sells health, beauty, food, and household products enhanced with herbs and herbal extracts. Its brands include Kandesn, Vitalite, SunBright, and SunSmile. Sunrider has manufacturing operations in China, Singapore, Taiwan, and the US. Its products are sold in more than 40 countries through multilevel marketing via distributors and directly to customers. In China, its products are sold in thousands of franchised stores to avoid regulations on direct-selling. It plans to copy that model in Japan.

Alimera Sciences' tunnel vision is a real asset. The biopharmaceutical company specializes in prescription ophthalmic pharmaceuticals, particularly those aimed at treating ocular diseases affecting the retina. Alimera's most advanced product candidate, Iluvien, is an insert about the size of a grain of rice that slowly releases a drug to the back of the eye used in the treatment of diabetic macular edema (DME); DME, a retinal disease affecting diabetics, can lead to severe vision loss and blindness. Iluvien is effective for up to 36 months and may also have the potential to affect other ophthalmic diseases, such as retinal vein occlusion (RVO). Alimera Sciences is looking to go public through an $80 million IPO.

Panacea Pharmaceuticals, Inc. was founded in 1999 and is based in Gaithersburg, Maryland. Panacea Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic and diagnostic products for cancer and diseases of the central nervous system. It focuses on the development of proteins and biochemical pathways related to cellular regulation and cell cycle abnormalities in oncology, as well as neurodegenerative diseases such as stroke, Alzheimer's disease, and Parkinson's disease. The company’s products include PAN-22, a human anit-HAAH monoclonal antibody for treatment of hepatocellular carcinoma; PAN-622, a Toxin Conjugate to treat carcinoma of the bile duct; and PAN-811 for the treatment of ischemic stroke. In addition, it develops blood, serum, and tissue tests to diagnose and monitor breast, colorectal, lung, and prostate cancers, as well as gene expression test that predicts the response of patients with Chronic Myelogenous Leukemia to imatinib.

Beijing Tongrentang Co., Ltd. company makes and sells a variety of traditional Chinese herbal medicines under the Tongrentang brand. Products include treatments for a number of maladies including colds and fevers, and preparations designed to improve circulation and kidney function. Tongrentang also exports its herbal remedies and has expanded beyond Chinese borders through a number of joint ventures and subsidiaries, establishing retail drug stores and clinics specializing in traditional Chinese medicine. The company's origins date back more than 300 years as a family business offering its remedies in Beijing during the Qing Dynasty.

The Mentholatum Company's best-known products, Mentholatum Deep Heating Rub, but they can probably find another of the company's bestsellers in their medicine cabinets -- Oxy Pads. The Mentholatum Company, a subsidiary of ROHTO Pharmaceutical, makes OTC products to relieve a variety of common ailments, including acne, cold sores, aches and pains, and chest congestion. In addition to the Oxy and Mentholatum brands, the firm sells its products under the WellPatch, Rohto, Fletcher's, Red Cross, Natural Ice, and Softlips monikers. ROHTO's Mentholatum companies have operations in more than a dozen countries and sells products in more than 150 countries.

NextGen Group, which does business as NextGen Sciences, puts proteins to the test. The research and development company provides protein analysis services for biotechnology and pharmaceutical customers around the world. Specific services include biomarker discovery and assay development, which are often used in the drug development process to test preclinical and clinical samples for therapeutic efficacy and safety. NextGen's biomarker projects focus on Alzheimer's disease and oncology, among other therapeutic areas. The group has operations in the US and the UK.

BD Biosciences company, a division of medical equipment firm Becton, Dickinson (BD), provides research supplies to the life sciences market. Its primary Cell Analysis unit offers cell imaging devices, flow cytometers (for cell sorting), and chemical reagents and antibodies (proteins) for cellular analysis. The Discovery Labware unit makes basic lab supplies including pipettes, tubes, and cell culture kits. In addition to scientific researchers and drug developers, BD Biosciences counts among its customers blood banks, hospitals, and clinical labs. The company sells its goods around the world through direct and indirect marketing reps and independent distributors.

Spherotech, Inc. company was founded in 1992. pherotech is very particular about its business. Spherotech company manufactures microparticles for the drug and medical device industries. Its product offerings include ferromagnetic, fluorescent, latex, paramagnetic, and various colored microparticles. Spherotech's products are used in applications such as fluorescence and enzyme immunoassay.

Callisto Pharmaceuticals, Inc. was founded in 1996 and is headquartered in New York, New York. Callisto Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses primarily on the development of drugs to treat gastrointestinal disorders and diseases, rheumatoid arthritis, neuroendocrine cancer, and acute leukemia. The company has three drugs in development, which include SP-304, a guanylyl cyclase C receptor agonist for the treatment of chronic constipation and constipation-predominant irritable bowel syndrome, which has completed Phase I clinical trial; Atiprimod, an orally administered drug with antiproliferative, anti-inflammatory and antiangiogenic activities, which is in Phase II development for advanced carcinoid cancer; and L-Annamycin, a novel compound from the anthracycline family of proven anti-cancer drugs for the treatment of leukemia. It also focuses on the development of Atiprimod for the treatment of rheumatoid arthritis. The company has license agreements with AnorMED Inc. to research, develop, sell, and commercialize the Atiprimod patent rights; and the University of Texas M.D. Anderson Cancer Center to develop and commercialize the L-Annamycin patent rights.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.